Transcenta

Today is World Osteoporosis Day🦴 Worldwide, one in three women and one in five men aged 50 years and over will suffer an osteoporotic fracture. Osteoporosis causes bones to become weak and fragile, so that they break easily - even as a result of a minor fall, a bump, a sneeze, or a sudden movement. Fractures caused by osteoporosis can be life-threatening and a major cause of pain and long-term disability. To become aware of any potential risk factors, you can take the IOF Osteoporosis Risk Check: https://lnkd.in/gegpt-w6 Let's spread awareness this World Osteoporosis Day! 

Transcenta sincerely invites you to our 2024 ESMO Business Update Call. Please scan the QR code or register through the below link to join the call. DATE: Sep 27, 2024 Friday TIME: 10:00am HKT LANGUAGE: English https://lnkd.in/gZ2sR7Ru

Transcenta announces the updated results from the cohort-G data for Osemitamab (TST001) plus Nivolumab and CAPOX as the first-line treatment for the patients with advanced G/GEJ cancer (TranStar102). The updated data continues to show encouraging efficacy from previously disclosed data at ASCO 2024. The results showed that in patients with known CLDN18.2 and PD-L1 status, the median progression-free survival (mPFS) reached 14.2 months for those with H/M CLDN18.2 expression, with a confirmed objective response rate of 68%. The vast majority of these patients are PD-L1 CPS<5. Read full news: https://lnkd.in/gXrjhZjP

In a recent interview with PharmaBoardroom, Transcenta's CEO, Dr. Xueming Qian, outlines company’s progress, including its Osemitamab (TST001) global Phase III trial and the continuous manufacturing capability it has developed, and weighs in on varying investor response as well as the Chinese biotech ecosystem.   Read the article to learn more about Transcenta‘s dedication to science. By focusing on scientific innovation and developing differentiated products that meet patient needs, we are paving a clear path forward.   https://lnkd.in/dz3JJkUq   #Healthcare #IndustryInsight #LeadingVoices #Biotech #Osemitamab #TST001

It's great that we are implementing a highly intensified hybrid continuous biomanufacturing process to produce Osemitamab, to improve quality and speed, while significantly reducing cost of goods to make it more affordable.  However, nothing is more exciting and rewarding than seeing the big difference we make for patients!!!

Transcenta announces study results from the Phase I/IIa Cohort-G data for Osemitamab (TST001) plus Nivolumab and CAPOX as the first-line treatment of patients with advanced G/GEJ cancer. The results showed that median progression-free survival (mPFS) reached 12.6 months in patients with H/M CLDN18.2 expression, any PD-L1 CPS, as well as in the 80% of patients with PD-L1 CPS<5. Using the group of patients with very low/no CLDN18.2 expression as surrogate control, the HR for the triple combination is 0.443 (95%CI, 0.205-0.958) in favor of the H/M expressors and in these patients, the confirmed overall response rate was 68%. Read full news: https://lnkd.in/gFCpfmQS #ASCO

The bioprocessing industry has identified an urgent need to intensify downstream operations, making them smaller, faster, and more cost-effective. Our collaboration with Merck has culminated in the development of a state-of-the-art, highly automated bioprocessing train for the manufacture of monoclonal antibodies and other biologics. This webinar will detail the bioprocessing template, operational paradigm, and the complexities involved in qualifying such an advanced manufacturing method. Join us: https://lnkd.in/dtgDqQBv

Transcenta announces that it is going to present results of cohort G from a phase I/IIa study: first-line Osemitamab (TST001) plus Nivolumab and CAPOX for advanced G/GEJ cancer (TranStar102) at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 from May 31 to June 4, 2024, in Chicago, IL, U.S.. Read full news: https://lnkd.in/gYE5-HXZ

Transcenta has presented 4 posters highlighting study results from ongoing trials related to Osemitamab (TST001) and TST003 at AACR Annual Meeting 2024, including development of Claudin 18.2 IHC 14G11 pharmDx as a clinical trial assay for the clinical development of anti-Claudin 18.2 monoclonal antibody Osemitamab (TST001) in G/GEJ adenocarcinoma; the safety, tolerability and pharmacokinetics profile of Osemitamab (TST001) administered as monotherapy or in combination with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors (TranStar101: a Phase I/IIa clinical trial); prevalence of Claudin 18.2 expression in gastric/gastroesophageal junction adenocarcinoma by Transcenta proprietary Claudin 18.2 assay from US and Chinese patients from Transtar101 and Transtar102 clinical trials, as well as a first-in-human, open-label, multi-center phase 1 study of TST003, a GREM 1 inhibitor, in subjects with locally advanced or metastatic solid tumors. Read full news: https://lnkd.in/gBTJDWcN #AACR

Transcenta and Agilent announce a collaboration to develop a Claudin18.2(CLDN18.2) companion diagnostic to support TranStar301 global Phase III pivotal trial of Osemitamab (TST001) in combination with Nivolumab and chemotherapy as first-line treatment in patients with CLDN18.2 expressing locally advanced or metastatic gastric or gastroesophageal (G/GEJ) adenocarcinoma. Read full news: https://lnkd.in/gTz346gw